FMP

FMP

Enter

ENTX - Entera Bio Ltd.

Financial Summary of Entera Bio Ltd.(ENTX), Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commerci

photo-url-https://financialmodelingprep.com/image-stock/ENTX.png

Entera Bio Ltd.

ENTX

NASDAQ

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

2.08 USD

-0.11 (-5.29%)

About

ceo

Ms. Miranda J. Toledano M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.enterabio.com

exchange

NASDAQ

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Ente...

CIK

0001638097

ISIN

IL0011429839

CUSIP

M40527109

Address

Kiryat Hadassah Minrav Buildin...

Phone

972 2 532 7151

Country

IL

Employee

17

IPO Date

Jun 28, 2018

Summary

CIK

0001638097

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

M40527109

ISIN

IL0011429839

Country

IL

Price

2.08

Beta

1.6

Volume Avg.

245.86k

Market Cap

74.5M

Shares

-

52-Week

0.52-3.35

DCF

0.37

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-7.43

P/B

-

Website

https://www.enterabio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ENTX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep